The proposed offer from Clayton, Dubilier & Rice (CD&R) would mean the sale of a 50% stake in Opella, which makes over-the-counter medicine such as Doliprane and Allegra.

Sanofi SA is in talks to sell a 50% controlling stake in its consumer health business to Clayton Dubilier & Rice, as the ...

Sanofi is in talks to sell a 50% controlling stake in its consumer health unit to CD&R. It is set to be one of the biggest deals this year, following similar moves by big pharma peers GSK Plc, ...

The French drugmaker laid out plans to separate its consumer division--home to brands such as Allegra, Dulcolax and IcyHot--from its innovative medicines and vaccines businesses a year ago. With its ...

Pfizer Inc. faced a challenging day on the New York Stock Exchange, with its stock price dropping 2.1% to $29.57. Despite this setback, the pharmaceutical behemoth received positive news from a Phase ...

An offer from US private equity firm Clayton, Dubilier & Rice has beaten rivals, pursuing French pharmaceutical company Sanofi’s consumer healthcare division, in what is set to be the largest European ...

GSK shares rose after the British drug major agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer. Write to Rob ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

The need for antiemetic drugs, which help prevent or relieve nausea and vomiting, is growing for several reasons. A key factor is the rising incidence of conditions and treatments that cause these ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

Two former Pfizer executives said they will not be involved with activist investor Starboard Value, which reportedly wants ...